N
Novartis
Reimagining Medicine
Basel, Switzerland (US: Cambridge, MA & East Hanover, NJ)
105,000+
About Novartis
Industry:
Pharmaceuticals
Founded:
1996
Founders:
Merger of Ciba-Geigy and Sandoz
Status:
Public (NYSE: NVS)
Funding & Growth
Total Raised:
N/A
Valuation:
$210B+ market cap
Stage:
Public
Key Investors:
Public markets
✓ Pros
- • Strong oncology and gene therapy pipeline
- • Heavy investment in data science (AI/ML)
- • Novartis Institutes for BioMedical Research (NIBR)
- • Cambridge, MA hub for US R&D
- • Good compensation and benefits
✗ Cons
- • Swiss headquarters (timezone challenges)
- • Large company bureaucracy
- • Recent restructuring and layoffs
- • Matrix organization complexity